The upregulation of PD-1 on T-cells and PD-L1 on tumor and T-cells following in vitro and in vivo TCB treatment led us to investigate whether combining CEA-TCB with PD-L1 blocking antibody could enhance the anti-tumor efficacy of CEA-TCB. Here, CEACAM5 is linked to neoplasm.